Personalized Cancer Vaccine for Treating Patients With Advanced Hepatocellular Cancer

Time: 10:30 am
day: Day Two

Details:

  • GT-EPIC™ DNA plasmid product designed and manufactured for each patient based on their tumor specific neoantigens
  • Discuss the interim clinical safety and efficacy data from the first 10 patients treated on study
  • The use of immuno-monitoring to assess the potency of the personalized cancer vaccine and mechanism of action of the targeted neoantigens in the clinic.

Speakers:

Niranjan Sardesai